Glycopeptide
Staphylococcus aureus (Oritavancin susceptible), Coagulase negative Staphylococci, Streptococcus pneumoniae, Streptococcus spp., Enterococcus spp. (Oritavancin susceptible), C. jeikeium, Clostridium spp., L. monocytogenes, Actinomyces
Oritavancin inhibits the transgycosylation of bacterial cell wall biosynthesis
No data
Cmax: 23.6mg/L (after 3mg/kg dose); Half-life: 132-356 hours; Volume of distribution: 0.65-1.92L/kg
Skin: Hypersensitivity
Pulmonary: Pulmonary embolism
Otic: Ototoxicity
Other: Tremors
Not commercially available
Not determined
Not yet determined
Unknown
Unknown
Therapeutic: Culture and sensitivities, serum levels, signs and symptoms of infection, white blood cell count
Not available